Abstract Body

Background: Adolescents and young adults infected with HIV face a lifetime of antiretroviral therapy (ART). Toxicities to antiretroviral therapy persist, including negative effects on bone renal function, and lipids; thus, limiting ARV exposure may still be of benefit. Assessing the impact of such interventions requires an understanding of their influence on viral suppression and T cell reconstitution and immune activation. Methodology: 75 subjects, ages 18-24, with CD4 T cells > 350 were started on FTC/TDF/ATVr as part of a randomized, unblended trial of therapy deintensification. Subjects who maintained an HIV viral load (VL) < 100 copies from weeks 24 through 48 were de-intensified to ATVr monotherapy at week 52 and to week 152. Subjects failed de-intensification for a confirmed VL> 400 copies or confirmed CD4 drop of > 30% from the average of the two peak values. Markers of T lymphocyte differentiation/activation were analyzed by multi-parameter LSR II flow cytometry to define naive, central memory (CM), and effector memory (EM) CD45RA and CD45RO subpopulations. Slopes of changes in T cell subsets and T cell activation from weeks 48 to 152 were estimated by a mixed effects model using a t-test to test whether mean slopes equaled zero. Results: 49 of 75 subjects met criteria at week 48 of ART for de-intensification. 25 of 49 (51%) remained suppressed on monotherapy to week 152. Total CD4 gains during ART persisted during de-intensification with ongoing significant increases in naive and CM (p=0.0167 and 0.0186, respectively) and a decrease in EMRA (p=0.0007) subsets from weeks 48 to 152. No significant changes occurred during monotherapy in any CD8 subpopulations. The significant increases in CD28 expression and decreases in CD38 and HLADR expression on CD8 subpopulations during ART were maintained during monotherapy without any significant increases to from week 48 through week 152. In 19 subjects failing de-intensification due to rebound virus, none demonstrated ATV resistance. Adherence was similar in those failing monotherapy up to the point of failure compared to those maintaining suppression. Conclusions: In subjects treated with ART with CD4> 350, de-intensification to monotherapy with ATVr following 48 weeks of ART is effective in maintaining naive and CM CD4 T cell reconstitution. No ATV resistance was noted in subjects with confirmed virologic failure. No increases in immune activation were found in those maintaining viral suppression. This strategy merits further investigation to determine its appropriateness selected populations.